An Intra-procedural Stent Thrombosis in a Prasugrel Resistant Patient Treated with Ticagrelor.
- Author:
Jung Ho PARK
1
;
Seung Ho HUR
;
Yun Kyeong CHO
;
Hyoung Seob PARK
;
Hyuck Jun YOON
;
Sang Hoon LEE
;
Hyung Seop KIM
;
Chang Wook NAM
;
Seong Wook HAN
Author Information
1. Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea. shhur@dsmc.or.kr
- Publication Type:Case Report
- Keywords:
Prasugrel resistance;
Stent thrombosis;
Ticagrelor
- MeSH:
Activation, Metabolic;
Blood Platelets;
Humans;
Middle Aged;
Myocardial Infarction;
Prasugrel Hydrochloride*;
Stents*;
Thrombosis*;
Ultrasonography
- From:Keimyung Medical Journal
2016;35(1):18-24
- CountryRepublic of Korea
- Language:English
-
Abstract:
Stent thromboses due to multifactorial causes including hypercoagulable conditions and high on treatment platelet reactivity (HTPR), which means a low response to anti-platelet therapy, especially clopidogrel. Prasugrel is a third generation thienopyridine and inactive pro-drug requiring metabolic activation in vivo, which improves the rate of HTPR with clopidogrel. This drug is mostly effective, with a potent, fast, and consistent anti-platelet action, but rare cases of inadequate platelet inhibition with prasugrel have been reported. Here we describe the case of a 47-year-old man who presented with a recurrent acute myocardial infarction and ST during an intravascular ultrasound pullback and was resistant to prasugrel, was successfully treated with ticagrelor.
